165 368

Cited 0 times in

Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy.

Authors
Lee, PH; Yong, SW; An, YS
Citation
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 49(12):2006-2011, 2008
Journal Title
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN
0161-55051535-5667
Abstract
We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy in patients with Parkinson disease dementia (PDD) to determine whether cognitive improvements would be reflected in changes of cerebral metabolic patterns, thus offering insight into the neural substrate of cognitive dysfunction in patients with PDD.



METHODS: We performed a serial PET study before (baseline) and after ChEI therapy on 10 patients with PDD, using statistical parametric mapping. Additionally, covariance analysis was performed to extract regions in which increased change in regional cerebral metabolism correlated significantly with increased Mini-Mental State Examination scores.



RESULTS: The statistical parametric mapping analysis indicated that significantly increased cerebral metabolism after ChEI therapy, compared with at baseline, was most evident in the left angular gyrus extending to the supramarginal area and left superior and middle frontal gyri. Additionally, cerebral metabolism was significantly increased in the right superior frontal and left middle orbitofrontal gyri. In contrast, the right fusiform gyrus showed significantly decreased metabolism after ChEI, compared with at baseline. In the correlation analysis, improvements in Mini-Mental State Examination scores after ChEI treatment were significantly associated with increased cerebral metabolism in the left supramarginal, orbitofrontal, and cingulate areas.



CONCLUSION: Our data suggest that prefrontal and parietal association areas may be relevant structures for the pharmacologic response to ChEI in patients with PDD.
MeSH terms
AgedAged, 80 and overAntiparkinson Agents/administration & dosageBrain/drug effectsBrain/metabolism*Cholinesterase Inhibitors/administration & dosage*Dementia/complicationsDementia/drug therapy*Dementia/metabolism*Dementia/radionuclide imagingFemaleFluorodeoxyglucose F18/diagnostic useFluorodeoxyglucose F18/pharmacokinetics*HumansMaleParkinson Disease/complicationsParkinson Disease/drug therapy*Parkinson Disease/metabolism*Parkinson Disease/radionuclide imagingRadiopharmaceuticals/diagnostic useRadiopharmaceuticals/pharmacokineticsTissue Distribution/drug effectsTreatment Outcome
DOI
10.2967/jnumed.108.054668
PMID
18997034
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Neurology
AJOU Authors
용, 석우
Full Text Link
Files in This Item:
Full-Text Not Available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse